Key Developments: AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

1.19USD
30 Jul 2014
Price Change (% chg)

$0.01 (+0.85%)
Prev Close
$1.18
Open
$1.17
Day's High
$1.19
Day's Low
$1.17
Volume
184,407
Avg. Vol
649,915
52-wk High
$1.75
52-wk Low
$0.99

Search Stocks

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris Inc appointed Chairman
Monday, 12 May 2014 07:30am EDT 

Aeterna Zentaris Inc:Appointed current President and CEO, David Dodd, as Chairman of Board.Board believes that with both roles being assumed by David Dodd.Former Chairman of Board and an independent director, will assume role of Lead Director.  Full Article

Aeterna Zentaris Inc. closes US$13.2 mln public offering of common shares and warrants
Tuesday, 14 Jan 2014 11:15am EST 

Aeterna Zentaris Inc:Says the closing of its previously announced public offering of 11.0 mln units.Says it generated net proceeds of about US$12.2 mln.Says each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit.Says Each warrant is exercisable for a period of five years at an exercise price of US$1.25 per share.Says Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC, H. C. Wainwright & Co., LLC and MLV & Co LLC acted as co-managers for the Offering.Says the company intends to use the net proceeds for future negative cash flow, general corporate purposes and working capital.  Full Article

Aeterna Zentaris Inc. announces pricing of US$13.2 mln public offering of common shares and warrants
Thursday, 9 Jan 2014 08:31am EST 

Aeterna Zentaris Inc:Says the pricing of its previously announced public offering of 11.0 mln units, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20per unit.Says each warrant will be exercisable for a period of five years following the issuance thereof at an exercise price of US$1.25 per share.Says the net proceeds from the Offering are expected to be about US$12.2 mln.Says Canaccord Genuity Inc. is acting as the sole book-running manager for the Offering. Maxim Group LLC, MLV & Co LLC and H. C. Wainwright & Co., LLC acted as co-managers for the Offering.Says the Offering is expected to close on or about Jan. 14.  Full Article

Aeterna Zentaris Inc. announces proposed public offering of common shares and warrants
Wednesday, 8 Jan 2014 04:05pm EST 

Aeterna Zentaris Inc:Says it has commenced an underwritten public offering of units, consisting of common shares and warrants to purchase common shares.Says the pricing and number of Units as well as the exercise price and duration of the warrants will be determined in the course of marketing.Says Canaccord Genuity is acting as sole book-running manager for the proposed Offering.  Full Article

Aeterna Zentaris Inc NDA for Macimorelin Acetate in AGHD accepted for filing by the FDA
Monday, 6 Jan 2014 12:00pm EST 

Aeterna Zentaris Inc:Says the U.S. Food and Drug Administration (FDA) has accepted for filing the company's New Drug Application (NDA) for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency (AGHD).Says the acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.  Full Article

Aeterna Zentaris Inc closes public offering of common shares and warrants
Monday, 25 Nov 2013 11:15am EST 

Aeterna Zentaris Inc:Says the closing of its previously announced public offering of 13.1 million units generating net proceeds of about $13.7 million.Says Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC act as co-manager for the Offering.Says it intends to use the net proceeds from the Offering to continue to fund its ongoing drug development activities.  Full Article

Aeterna Zentaris Inc. Announces Pricing of USD15.1 Million Public Offering of Common Shares and Warrants
Wednesday, 20 Nov 2013 08:22am EST 

Aeterna Zentaris Inc. announced the pricing of its previously announced public offering of 13.1 million units (the Offering), with each unit consisting of one common share and one whole warrant to purchase one common share, at a purchase price of USD1.15 per unit. Each warrant will be exercisable for a period of five years following the issuance thereof at an exercise price of USD1.60 per share. Net proceeds from the Offering are expected to be approximately USD13.7 million, after deducting underwriting commissions and other expenses related to the Offering. Canaccord Genuity Inc. is acting as the sole book-running manager for the Offering. Maxim Group LLC acted as co-manager for the Offering. The Offering is expected to close on or about November 25, 2013, subject to customary closing conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approvals of the Toronto Stock Exchange and the NASDAQ Capital Market. The Company intends to use the net proceeds from the Offering to continue to fund its ongoing drug development activities, primarily for the advancement of its zoptarelin doxorubicin (AEZS-108) program, secondly for its macimorelin acetate (AEZS-130) program, including the preparation of its commercial launch, as well as for the potential addition of commercialized products to the Company's pipeline, future negative cash flow, general corporate purposes and working capital.  Full Article

AEterna Zentaris Inc Announces Proposed Public Offering Of Common Shares And Warrants
Tuesday, 19 Nov 2013 04:05pm EST 

Aeterna Zentaris Inc announced that it has commenced an underwritten public offering of units (the "Offering"), consisting of common shares and warrants to purchase common shares. The pricing and number of Units as well as the exercise price and duration of the warrants will be determined in the course of marketing. Canaccord Genuity is acting as sole book-running manager for the proposed Offering.  Full Article

AEterna Zentaris Inc Submits New Drug Application to FDA for Macimorelin Acetate (AEZS-130) for Evaluation of AGHD
Tuesday, 5 Nov 2013 07:30am EST 

Aeterna Zentaris Inc announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for its ghrelin agonist, macimorelin acetate (AEZS-130). Phase 3 data have demonstrated that the compound has the potential to become the first orally-approved product that induces growth hormone release to evaluate adult growth hormone deficiency, with accuracy comparable to available intravenous and intramuscular testing procedures.  Full Article

AEterna Zentaris Inc Completes $7.8 Million Registered Direct Offering
Tuesday, 30 Jul 2013 06:00pm EDT 

AEterna Zentaris Inc announced that it has completed its previously announced registered direct offering of $7.8 million of units comprised of common shares and common share purchase warrants to certain institutional investors. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $7 million. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used to continue to fund the Company's ongoing drug development activities, primarily for the advancement of its zoptarelin doxorubicin program, secondly for its macimorelin acetate program, as well as for general corporate purposes and working capital. Burrill Securities LLC acted as the exclusive placement agent for the transaction. As of July 30, 2013 and after issuing 5.2million common shares at the closing of this offering, the Company had approximately 31.2 million common shares issued and outstanding, without giving effect to or assuming the exercise of any outstanding warrants.  Full Article

Search Stocks